William Blair Has Negative Estimate for Amedisys Q1 Earnings

Amedisys, Inc. (NASDAQ:AMED) – Equities researchers at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of Amedisys in a report issued on Thursday, February 27th. William Blair analyst M. Larew now expects that the health services provider will post earnings per share of $0.98 for the quarter, down from their previous forecast of $1.01. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reissued an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a report on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Trading Down 0.0 %

Shares of Amedisys stock opened at $91.57 on Friday. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of 36.34, a P/E/G ratio of 1.78 and a beta of 0.73. The business has a fifty day simple moving average of $91.26 and a two-hundred day simple moving average of $93.25.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. increased its position in shares of Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the period. HBW Advisory Services LLC acquired a new stake in shares of Amedisys during the fourth quarter valued at about $38,000. Versant Capital Management Inc boosted its stake in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 183 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Amedisys during the fourth quarter valued at about $55,000. Finally, KBC Group NV acquired a new stake in shares of Amedisys during the third quarter valued at about $63,000. Institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.